Numerical Chromosomal Aberrations in Borderline,Benign,and Malignant Epithelial Tumors of the Ovary: Correlation With p53 Protein Overexpression and Ki-67

Abstract

Objective: Ovarian tumors of low malignant potential (borderline turmors) have a 5-year survival rate of 69-98%, illustrating that while the prognosis is better than in the typical epithelial carcinoma, a significant number of women still succumb to this disease. The aim of our study was to elucidate the role of numerical chromosomal aberrations in borderline tumors of the ovary in comparison with benign and malignant epithelial tumors in an effort to develop parameters to differentiate prospectively borderline lesions from benign and invasive tumors.

Methods: Cytologic imprints of surgical specimens of 46 ovarian tumors of low-malignant potential, 17 invasive epithelial carcinomas of the ovary, and 18 benign epithelial tumors of the ovary were examined for numerical chromosomal aberrations (trisomy 7, trisomy 12, and trisomy 17) by fluorescence in situ hybridization (FISH).

Results: In benign tumors no evidence of trisomy 7 and 17 was present. Trisomy 12 was detected in six cases (33.3%). We did not find p53 protein overexpression in any case. Ki-67 stained positive in three cases (16.7%). In borderline tumors trisomy 12 was detected in 33 patients (71.7%). Numerical aberrations of chromosome 17 were absent in all cases. Fourteen patients (30.4%) showed trisomy 7. No immunohistochemical staining reaction for p53 protein was found. Staining of the proliferation marker Ki-67 was observed in two cases (4.3%). In malignant epithelial tumors of the ovary, trisomy 7, trisomy 12, and trisomy 17 were detected in 14 (82.3%), 11 (64.7%), and 5 (29.4%) cases, respectively. Four tumors (23.5%) showed immunohistochemically detected p53 protein overexpression. Thirteen tumors (76.5%) stained for Ki-67.

Conclusion: Our results indicate that trisomy 7 argues against benign disease. Trisomy 17 was specific for invasive disease, while trisomy 12 is common in borderline tumors of the ovary.

Keywords

FISH immunohistochemistry borderline tumors of the ovary numerical chromosomal aberrations

Get full access to this article

View all access options for this article.

References

1. Silva EG , Kurman RJ , Russell P , Scully RE . Symposium: Ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996;15:281-302.

2. Serov SF , Scully RE , Sobin LH . International histologic classification of tumours. Vol. 9. Histological typing of ovarian tumours. Geneva: World Health Organization, 1973.

3. Hart WR , Norris HJ . Borderline and malignant tumors of the ovary. Cancer 1973;31:1031-1045.

4. Bell DA , Scully RE . Ovarian serous borderline tumors with stromal microinvasion: A report of 21 cases. Hum Pathol 1990;21:397-403.

5. Hopkins MP , Kumar NB , Morley GW . An assessment of pathologic features and treatment modalities in ovarian tumors of low malignant potential. Obstet Gynecol 1987;70:923-929.

6. Chambers JT , Merino MJ , Kohorn EI , Schwartz PE . Borderline ovarian tumors. Am J Obstet Gynecol 1988;159:1088-1094.

7. Pinkel D , Straume T , Gray JW . Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridisation. Proc Natl Acad Sci USA 1986;83:2934-2938.

8. Wertheim I , Muto MG , Welch WR , Bell DA , Berkowitz RS , Mok SC . P53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-1550.

9. Berchuck A , Kohler MF , Hopkins MP , et al. Overexpression of P53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-236.

10.

10. Kupryjanczyk J , Bell DA , Yandell DW , Scully RE , Thor AD . P53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-676.

11.

11. Isola J , Kallioniemi OP , Korte JM , et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay and patient survival. J Pathol 1990;162:295-301.

12.

12. Henriksen R , Strang P , Wilander E , Bäckström T , Tribukait B , Öberg K . p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-306.

13.

13. Gallion HH , Powell DE , Smith LW , et al. Chromosome abnormalities in human epithelial ovarian malignacies. Gynecol Oncol 1990;38:473-477.

14.

14. Persons DL , Hartmann LC , Herath JF , Keeney GL , Jenkins RB . fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors. Am J Clin Pathol 1994;102:775-779.

15.

15. Shashi V , Golden WL , von Kap-Herr C , Andersen WA , Gaffey MJ . Interphase fluorescence in situ hybridization for trisomy 12 on archival ovarian sex cord-stromal tumors. Gynecol Oncol 1994;55:349-354.

16.

16. Halperin D , Visscher DW , Wallis T , Lawrence D . Evaluation of chromosome 12 copy number in ovarian granulosa cell tumors using interphase cytogenetics. Int J Gynecol Pathol 1995;14:319-323.

17.

17. Runnebaum IB , Kieback DG , Möbus VJ , Tong XW , Kreienberg R . Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol Oncol 1996;61:266-271.